BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 11801555)

  • 21. Genetic and immunophenotype analyses of TP53 in bladder cancer: TP53 alterations are associated with tumor progression.
    Erill N; Colomer A; Verdú M; Román R; Condom E; Hannaoui N; Banús JM; Cordon-Cardo C; Puig X
    Diagn Mol Pathol; 2004 Dec; 13(4):217-23. PubMed ID: 15538112
    [TBL] [Abstract][Full Text] [Related]  

  • 22. mdm-2 expression correlates with wild-type p53 status in esophageal adenocarcinoma.
    Soslow RA; Altorki NK; Yang G; Xie D; Yang CS
    Mod Pathol; 1999 Jun; 12(6):580-6. PubMed ID: 10392633
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein.
    Landers JE; Cassel SL; George DL
    Cancer Res; 1997 Aug; 57(16):3562-8. PubMed ID: 9270029
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.
    Pfister C; Moore L; Allard P; Larue H; Lacombe L; Têtu B; Meyer F; Fradet Y
    Clin Cancer Res; 1999 Dec; 5(12):4079-84. PubMed ID: 10632343
    [TBL] [Abstract][Full Text] [Related]  

  • 25. p53 protein expression in breast carcinomas. Comparative study with the wild type p53 induced proteins mdm2 and p21/waf1.
    Giannikaki E; Kouvidou C; Tzardi M; Stefanaki K; Koutsoubi K; Gregoriou M; Zois E; Kakolyris S; Mavroudi C; Delides G; Georgoulias V; Kanavaros P
    Anticancer Res; 1997; 17(3C):2123-7. PubMed ID: 9216675
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutations in the TP53 gene and protein expression of p53, MDM 2 and p21/WAF-1 in primary cervical carcinomas with no or low human papillomavirus load.
    Helland A; Karlsen F; Due EU; Holm R; Kristensen G; Børresen-Dale Al
    Br J Cancer; 1998 Jul; 78(1):69-72. PubMed ID: 9662253
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phage-peptide display identifies the interferon-responsive, death-activated protein kinase family as a novel modifier of MDM2 and p21WAF1.
    Burch LR; Scott M; Pohler E; Meek D; Hupp T
    J Mol Biol; 2004 Mar; 337(1):115-28. PubMed ID: 15001356
    [TBL] [Abstract][Full Text] [Related]  

  • 28. P53 and MDM2 co-expression in tobacco and betel chewing-associated oral squamous cell carcinomas.
    Shwe M; Chiguchi G; Yamada S; Nakajima T; Maung KK; Takagi M; Amagasa T; Tsuchida N
    J Med Dent Sci; 2001 Dec; 48(4):113-9. PubMed ID: 12160248
    [TBL] [Abstract][Full Text] [Related]  

  • 29. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer.
    Shariat SF; Tokunaga H; Zhou J; Kim J; Ayala GE; Benedict WF; Lerner SP
    J Clin Oncol; 2004 Mar; 22(6):1014-24. PubMed ID: 14981102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. p53 mutations in bladder tumors inactivate the transactivation of the p21 and Bax genes, and have a predictive value for the clinical outcome after bacillus Calmette-Guerin therapy.
    Pfister C; Flaman JM; Dunet F; Grise P; Frebourg T
    J Urol; 1999 Jul; 162(1):69-73. PubMed ID: 10379742
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in liver cirrhosis and hepatocellular carcinoma.
    Jablkowski M; Bocian A; Bialkowska J; Bartkowiak J
    J Exp Clin Cancer Res; 2005 Mar; 24(1):117-25. PubMed ID: 15943041
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TP53 pathway analysis in paediatric Burkitt lymphoma reveals increased MDM4 expression as the only TP53 pathway abnormality detected in a subset of cases.
    Leventaki V; Rodic V; Tripp SR; Bayerl MG; Perkins SL; Barnette P; Schiffman JD; Miles RR
    Br J Haematol; 2012 Sep; 158(6):763-71. PubMed ID: 22845047
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of p53 and mdm2 proteins in malignant fibrous histiocytoma in absence of gene alteration: prognostic significance.
    Molina P; Pellín A; Navarro S; Boix J; Carda C; Llombart-Bosch A
    Virchows Arch; 1999 Dec; 435(6):596-605. PubMed ID: 10628802
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inactivation of the p53 pathway in prostate cancer: impact on tumor progression.
    Osman I; Drobnjak M; Fazzari M; Ferrara J; Scher HI; Cordon-Cardo C
    Clin Cancer Res; 1999 Aug; 5(8):2082-8. PubMed ID: 10473090
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry.
    Nenutil R; Smardova J; Pavlova S; Hanzelkova Z; Muller P; Fabian P; Hrstka R; Janotova P; Radina M; Lane DP; Coates PJ; Vojtesek B
    J Pathol; 2005 Nov; 207(3):251-9. PubMed ID: 16161005
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunohistochemical expression of p53, bcl-2, mdm2 and waf1/p21 proteins in colorectal adenocarcinomas.
    Valassiadou KE; Stefanaki K; Tzardi M; Datseris G; Georgoulias V; Melissas J; Tsiftsis DD; Delides G; Kanavaros P
    Anticancer Res; 1997; 17(4A):2571-6. PubMed ID: 9252682
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of p53 mutations and the expression of p53 and p21WAF1/CIP1 protein in 15 cases of sebaceous carcinoma of the eyelid.
    Kiyosaki K; Nakada C; Hijiya N; Tsukamoto Y; Matsuura K; Nakatsuka K; Daa T; Yokoyama S; Imaizumi M; Moriyama M
    Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):7-11. PubMed ID: 19628749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-resolution array-based comparative genomic hybridization of bladder cancers identifies mouse double minute 4 (MDM4) as an amplification target exclusive of MDM2 and TP53.
    Veerakumarasivam A; Scott HE; Chin SF; Warren A; Wallard MJ; Grimmer D; Ichimura K; Caldas C; Collins VP; Neal DE; Kelly JD
    Clin Cancer Res; 2008 May; 14(9):2527-34. PubMed ID: 18451213
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The HAUSP gene plays an important role in non-small cell lung carcinogenesis through p53-dependent pathways.
    Masuya D; Huang C; Liu D; Nakashima T; Yokomise H; Ueno M; Nakashima N; Sumitomo S
    J Pathol; 2006 Apr; 208(5):724-32. PubMed ID: 16450335
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alterations of cell cycle regulators in localized synovial sarcoma: A multifactorial study with prognostic implications.
    Antonescu CR; Leung DH; Dudas M; Ladanyi M; Brennan M; Woodruff JM; Cordon-Cardo C
    Am J Pathol; 2000 Mar; 156(3):977-83. PubMed ID: 10702413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.